APO RESEARCH · REPORT
Eosinophilic Esophagitis Drug
Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Product & engineering
Understand the product.
Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.
This report studies the eosinophilic esophagitis drug market.
Selected research
Industry Research
Eosinophilic Esophagitis Drug Industry Research Report 2026
Market perspective
Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.
This report studies the eosinophilic esophagitis drug market.
Read the full market overview
AstraZeneca, GSK and Bayer are the leading producers of eosinophilic esophagitis drug, which together account for about 80% of the market.
North America is the leading region, accounting for more than 30% of the market, followed by Europe at nearly 30%.
Report Scope
This report quantifies the global Eosinophilic Esophagitis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Eosinophilic Esophagitis Drug Market by Company
AstraZeneca
GSK
Bayer
Adare Pharmaceuticals
DBV Technologies
Dr. Falk Pharma
Quorum Innovations
Takeda
Calypso
Celgene
Regeneron
Eosinophilic Esophagitis Drug Segment by Type
Budesonide
Fluticasone
Others
Eosinophilic Esophagitis Drug Segment by Application
Hospitals
Clinics
Drugstore
Eosinophilic Esophagitis Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eosinophilic Esophagitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Eosinophilic Esophagitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eosinophilic Esophagitis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Eosinophilic Esophagitis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Eosinophilic Esophagitis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Eosinophilic Esophagitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Budesonide
- Fluticasone
- Others
Applications
- Hospitals
- Clinics
- Drugstore
Companies covered
- AstraZeneca
- GSK
- Bayer
- Adare Pharmaceuticals
- DBV Technologies
- Dr. Falk Pharma
- Quorum Innovations
- Takeda
- Calypso
- Celgene
- Regeneron
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Eosinophilic Esophagitis Drug Market Size (2021-2032)
- 2.2.2 Global Eosinophilic Esophagitis Drug Sales (2021-2032)
- 2.2.3 Global Eosinophilic Esophagitis Drug Market Average Price (2021-2032)
- 2.3 Eosinophilic Esophagitis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Budesonide
- 2.3.3 Fluticasone
- 2.3.4 Others
- 2.4 Eosinophilic Esophagitis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Drugstore
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Eosinophilic Esophagitis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Eosinophilic Esophagitis Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Eosinophilic Esophagitis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Eosinophilic Esophagitis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Eosinophilic Esophagitis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Eosinophilic Esophagitis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Eosinophilic Esophagitis Drug, Product Type & Application
- 3.8 Global Manufacturers of Eosinophilic Esophagitis Drug, Established Date
- 3.9 Global Eosinophilic Esophagitis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca
- 4.1.1 AstraZeneca Company Information
- 4.1.2 AstraZeneca Business Overview
- 4.1.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio
- 4.1.5 AstraZeneca Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Eosinophilic Esophagitis Drug Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Bayer
- 4.3.1 Bayer Company Information
- 4.3.2 Bayer Business Overview
- 4.3.3 Bayer Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer Eosinophilic Esophagitis Drug Product Portfolio
- 4.3.5 Bayer Recent Developments
- 4.4 Adare Pharmaceuticals
- 4.4.1 Adare Pharmaceuticals Company Information
- 4.4.2 Adare Pharmaceuticals Business Overview
- 4.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio
- 4.4.5 Adare Pharmaceuticals Recent Developments
- 4.5 DBV Technologies
- 4.5.1 DBV Technologies Company Information
- 4.5.2 DBV Technologies Business Overview
- 4.5.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio
- 4.5.5 DBV Technologies Recent Developments
- 4.6 Dr. Falk Pharma
- 4.6.1 Dr. Falk Pharma Company Information
- 4.6.2 Dr. Falk Pharma Business Overview
- 4.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio
- 4.6.5 Dr. Falk Pharma Recent Developments
- 4.7 Quorum Innovations
- 4.7.1 Quorum Innovations Company Information
- 4.7.2 Quorum Innovations Business Overview
- 4.7.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio
- 4.7.5 Quorum Innovations Recent Developments
- 4.8 Takeda
- 4.8.1 Takeda Company Information
- 4.8.2 Takeda Business Overview
- 4.8.3 Takeda Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Takeda Eosinophilic Esophagitis Drug Product Portfolio
- 4.8.5 Takeda Recent Developments
- 4.9 Calypso
- 4.9.1 Calypso Company Information
- 4.9.2 Calypso Business Overview
- 4.9.3 Calypso Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Calypso Eosinophilic Esophagitis Drug Product Portfolio
- 4.9.5 Calypso Recent Developments
- 4.10 Celgene
- 4.10.1 Celgene Company Information
- 4.10.2 Celgene Business Overview
- 4.10.3 Celgene Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Celgene Eosinophilic Esophagitis Drug Product Portfolio
- 4.10.5 Celgene Recent Developments
- 4.11 Regeneron
- 4.11.1 Regeneron Company Information
- 4.11.2 Regeneron Business Overview
- 4.11.3 Regeneron Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Regeneron Eosinophilic Esophagitis Drug Product Portfolio
- 4.11.5 Regeneron Recent Developments
5 Global Eosinophilic Esophagitis Drug Market Scenario by Region
- 5.1 Global Eosinophilic Esophagitis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Eosinophilic Esophagitis Drug Sales by Region: 2021-2032
- 5.2.1 Global Eosinophilic Esophagitis Drug Sales by Region: 2021-2026
- 5.2.2 Global Eosinophilic Esophagitis Drug Sales by Region: 2027-2032
- 5.3 Global Eosinophilic Esophagitis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Eosinophilic Esophagitis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Eosinophilic Esophagitis Drug Revenue by Region: 2027-2032
- 5.4 North America Eosinophilic Esophagitis Drug Market Facts & Figures by Country
- 5.4.1 North America Eosinophilic Esophagitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
- 5.4.3 North America Eosinophilic Esophagitis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Eosinophilic Esophagitis Drug Market Facts & Figures by Country
- 5.5.1 Europe Eosinophilic Esophagitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Eosinophilic Esophagitis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Eosinophilic Esophagitis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Eosinophilic Esophagitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Eosinophilic Esophagitis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Eosinophilic Esophagitis Drug Market Facts & Figures by Country
- 5.7.1 South America Eosinophilic Esophagitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
- 5.7.3 South America Eosinophilic Esophagitis Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Eosinophilic Esophagitis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Eosinophilic Esophagitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Eosinophilic Esophagitis Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Eosinophilic Esophagitis Drug Sales by Type (2021-2032)
- 6.1.1 Global Eosinophilic Esophagitis Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Eosinophilic Esophagitis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Eosinophilic Esophagitis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Eosinophilic Esophagitis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Eosinophilic Esophagitis Drug Sales by Application (2021-2032)
- 7.1.1 Global Eosinophilic Esophagitis Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Eosinophilic Esophagitis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Eosinophilic Esophagitis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Eosinophilic Esophagitis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Eosinophilic Esophagitis Drug Value Chain Analysis
- 8.1.1 Eosinophilic Esophagitis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Eosinophilic Esophagitis Drug Production Mode & Process
- 8.2 Eosinophilic Esophagitis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Eosinophilic Esophagitis Drug Distributors
- 8.2.3 Eosinophilic Esophagitis Drug Customers
9 Global Eosinophilic Esophagitis Drug Analyzing Market Dynamics
- 9.1 Eosinophilic Esophagitis Drug Industry Trends
- 9.2 Eosinophilic Esophagitis Drug Industry Drivers
- 9.3 Eosinophilic Esophagitis Drug Industry Opportunities and Challenges
- 9.4 Eosinophilic Esophagitis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst